Skip to main content

Table 2 Clinical trial outcome measures developed by the Pediatric Rheumatology Collaborative Study Group Leadership in collaboration with other pediatric rheumatology networks

From: Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

Juvenile Idiopathic Arthritis Core set of Outcome Measuresa [35]
Preliminary Definition of Improvementa [36]
Preliminary Flare Criteriaa [37]
Provisional criteria for inactive disease & clinical remissiona [38]
Macrophage Activation Syndromea [39]
Systemic Lupus Erythematosus Disease activity [40]
Disease damage [41]
Core Set of Outcome Measuresa [42]
Provisional Improvement Criteriab [43]
Preliminary Flare Criteriab [44]
Preliminary Inactive Disease Criteriab [45]
Juvenile Dermatomyositis Childhood Myositis Activity Assessment Scalec [46]
Core set measures of disease activity and damagea [42]
Provisional Criteria for Response to Therapya [47]
  1. aDeveloped in collaboration with Pediatric Rheumatology International Trials Organization (PRINTO)
  2. bDeveloped in collaboration with PRINTO and Childhood Arthritis and Rheumatology Research Alliance (CARRA)
  3. cDeveloped in collaboration with Juvenile Dermatomyositis Disease Activity Collaborative Study Group (predecessor to International Myositis Assessment and Clinical Studies Group)